IP Library Granted Patent US 8,383,617
Granted Patent B2
US 8,383,617 · App. 12/525,381 · Granted Feb 26, 2013

Treatment of protein aggregation diseases

Inventors: Stuart Mark Wilson (London, GB); Christopher John Stanley (London, GB)
Assignee: PAD Pharma Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,617
App. No.
12/525,381
Granted
Feb 26, 2013
Kind
B2
Abstract

A method of treatment for the prevention or therapy of a protein aggregation disease includes the administration in combination of a first active medicament and a second active medicament, wherein the first active medicament is active to impede aggregation of amyloid protein and the second active medicament is active to disaggregate previously formed aggregates of amyloid protein.

Claims (5)

1. A method for treatment for the therapy of a protein aggregation disease comprising the administration of a synergistic effective amount of a combination comprising a first active medicament, wherein the first medicament is fluphenazine, and a second active medicament, wherein the second medicament is trimipramine, wherein the first active medicament is administered to impede aggregation of amyloid protein and the second active medicament is administered to disaggregate previously formed aggregates of amyloid protein.

2. A method as claimed in claim 1 , wherein said treatment is administered to a mammal that has been tested for the presence of aggregated amyloid in a sample derived therefrom and has tested positive.

3. A method as claimed in claim 1 , wherein said treatment is administered to a mammal that is known to have been exposed to an infectious source of protein aggregation disease under potentially infectious circumstances.

4. A method as claimed in claim 1 , wherein said treatment is administered to a mammal that has been tested for a genetic predisposition to contracting a protein aggregation disease and which has tested positive.

5. A method as claimed in claim 1 , further comprising conducting a test for the presence of a protein aggregation disease prior to, during, and/or after conducting said treatment.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2018
From: MICROSENS BIOPHAGE LTD
To: PHARMAKURE LTD
Reel/Frame 046071/0841 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2017
From: PAD PHARMA LIMITED
To: MICROSENS BIOPHAGE LTD
Reel/Frame 044286/0135 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2009
From: WILSON, STUART MARK; STANLEY, CHRISTOPHER JOHN
To: PAD PHARMA LIMITED
Reel/Frame 023622/0014 →
Priority Claims (2)
GB 0701970.6 · Feb 1, 2007 · national
GB 0704105.6 · Mar 2, 2007 · national
Continuity (1)
Related Publication 20100035859A1 · Feb 11, 2010